Drug Database
Back to search

Germany· DE-A57-fed960de77b42956

Leustatin

A cladribine product containing cladribine, registered in Germany by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L04AA40

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedLeustatinATCL04AA40REGISTER NO.DE-A57-fed960de77b429…PACKS LISTED0CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cladribineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cladribine is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AA40 (cladribine), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 8 of them publish a price we can compare per daily dose
Search cladribine products by name

Cladribine · ATC L04AA40

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cladribine costs, country by country.

Normalised to the WHO defined daily dose (0.34 mg), the median price runs from $0.048 in France to $90.83 in Switzerland — a ×1908 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cladribine · price per daily dose (0.34 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$90.83
  • FR France$0.048
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

EMA Article 57 (European Union)
Active substance
Cladribine
Manufacturer
Atnahs Pharma Netherlands B.V.
Country
Germany (DE)
ATC code
L04AA40
ATC class
Cladribine
Defined daily dose
0.34 mg, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

409 interactions on record for cladribine.

Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cladribine against other medicinesHow interaction checks work

Cladribine · interactions on record

409 records

  • 326 severe
  • 79 moderate
  • 4 info

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cladribine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cladribine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Leuject
  • Belgium · Leustatin
  • Bulgaria · Леуджект
  • Czechia · Leuject
  • Spain · Leustatin
  • Finland · Leuject
  • France · Leustatine
  • United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
  • Greece · Leustatin
  • Croatia · Leuject
  • Hungary · Leuject
  • Iceland · Mavenclad
  • Italy · Leustatin
  • Liechtenstein · Mavenclad
  • Luxembourg · Leustatin
  • Netherlands · Leustatin
  • Norway · Leuject, Mavenclad
  • Poland · Biodribin, Leuject
  • Portugal · Cladribina Generis, Leustatin
  • Romania · Leuject
  • Sweden · Leuject
  • Slovenia · Leuject

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a959ef1a-554f-4ec1-83a3-ed8744d696ec
GET /v1/drugs/a959ef1a-554f-4ec1-83a3-ed8744d696ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Subcutaneous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Cladribine",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}
API referenceMCP serverPlans

See everything about cladribine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console